{"id":57231,"date":"2024-07-15T12:03:45","date_gmt":"2024-07-15T12:03:45","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/07\/15\/i-mab-announces-leadership-transitions\/"},"modified":"2024-07-15T12:03:45","modified_gmt":"2024-07-15T12:03:45","slug":"i-mab-announces-leadership-transitions","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/i-mab-announces-leadership-transitions\/","title":{"rendered":"I-Mab Announces Leadership Transitions"},"content":{"rendered":"
\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

ROCKVILLE, Md.<\/span><\/span>, July 15, 2024<\/span><\/span> \/PRNewswire\/ — I-Mab (NASDAQ: IMAB) (the “Company” or “I-Mab”), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. Wei Fu<\/span> as the Chairman of the Board of Directors. He succeeds Dr. Pamela M. Klein<\/span>, who steps down from I-Mab’s Board of Directors and the Interim Chairperson position.\u00a0 Mr. Wei Fu<\/span> has served as a member of the I-Mab Board of Directors since June 2018<\/span> and is the Chief Executive Officer of CBC Group, a healthcare asset management firm and the founding and largest shareholder of I-Mab.<\/p>\n

\n<\/p><\/div>\n

In addition, Mr. Raj Kannan intends to leave his role as Chief Executive Officer and as a member of the Company’s Board of Directors, effective July 15<\/span>, 2024.\u00a0 Mr. Kannan will stay as an advisor of the Company until July 31, 2024<\/span> to assist with the transition.\u00a0 This decision follows a mutual agreement with the Board of Directors. \u00a0Dr. Sean Xi-Yong Fu<\/span> has assumed the role of Interim Chief Executive Officer and a member of the Board of Directors, effective July 15, 2024<\/span>.<\/p>\n

In addition to being Interim CEO and Director of I-Mab, Dr. Sean Fu<\/span> is also an Operating Partner of ABio-X, an incubation platform for life sciences companies. Before joining ABio-X, Dr. Fu was co-founder and CEO of RVAC Medicines, an mRNA platform company. Prior to founding RVAC, Dr. Fu was Group VP and head of International R&D for Luye Pharma, overseeing organizations in Boston<\/span>, Princeton<\/span>, Germany<\/span>, Switzerland<\/span> and Japan<\/span>. He was also the CEO of GeneLeap, a Luye subsidiary company focused on DNA and RNA therapeutics. Previously, Dr. Fu worked at Merck & Co. for 15 years with responsibilities covering R&D, business development, finance and operational management. His work at Merck included management of the finances for the late-stage clinical portfolio and leading the integration of global R&D network following the landmark $42 billion<\/span> merger between Merck and Schering-Plough. Dr. Fu earned a Master’s and PhD degrees in materials science and engineering from Ohio State University<\/span>, and an MBA from the Wharton School of University of Pennsylvania<\/span>.<\/p>\n

“Our dedication to scientific innovation and to our strategic objectives for bringing life-changing drugs to market is unwavering,” said Mr. Wei Fu<\/span>, I-Mab’s new Chairman.\u00a0“I am confident Dr. Fu will provide invaluable leadership for our talented team in advancing our innovative R&D pipeline and our business in his role as Interim CEO. He brings a wealth of biotech industry experience and relationships to support the Board as we secure the best permanent leader to take I-Mab forward and drive our growth opportunities and value for shareholders. \u00a0Meanwhile, we’d like to extend our gratitude to Ms. Klein and Mr. Kannan for their support and contributions to I-Mab.”<\/p>\n

“I’m grateful for this opportunity and excited to lead I-Mab. \u00a0During this pivotal time, I am dedicated to leading I-Mab through the completion of its transformation to becoming a U.S.-based biotech company, to build the Company’s highly differentiated pipeline, and work with our Board of Directors, leadership team and talented employees and partners to create new treatment options for patients around the world,” said Dr. Sean Fu<\/span>, Interim CEO of I-Mab.<\/p>\n

In addition to these\u00a0leadership transitions, the Company also announced certain changes to the composition of the Board of Directors and its committees:<\/p>\n